Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Northwest Biotherapeutics
Nieuws
Northwest Biotherapeutics
NWBO
OTC
: NWBO
| ISIN: US66737P6007
9/05/2025
0,276 USD
(+1,47%)
(+1,47%)
9/05/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
3 juli 2024 ·
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
· Persbericht
17 juni 2024 ·
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
· Persbericht
21 maart 2024 ·
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
· Persbericht
6 februari 2024 ·
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
· Persbericht
21 december 2023 ·
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
· Persbericht
13 oktober 2023 ·
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
· Persbericht
12 september 2023 ·
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
· Persbericht
29 augustus 2023 ·
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
· Persbericht
21 maart 2023 ·
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
· Persbericht
12 maart 2023 ·
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
· Persbericht
6 januari 2023 ·
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
· Persbericht
17 november 2022 ·
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
· Persbericht
23 augustus 2022 ·
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
· Persbericht
6 juli 2022 ·
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
· Persbericht
6 juni 2022 ·
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
· Persbericht
10 mei 2022 ·
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
· Persbericht
4 mei 2022 ·
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
· Persbericht
17 februari 2022 ·
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
· Persbericht
29 november 2021 ·
Northwest Biotherapeutics Announces $15 Million Financing
· Persbericht
28 oktober 2021 ·
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe